Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Vormoor, Britta ^a,b   Knizia, Henrike K ^a,c   Batey, Michael A ^a,d   Almeida, Gilberto S ^a,e   Wilson, Ian ^a   Dildey, Petra ^b   Sharma, Abhishek ^a   Blair, Helen ^a   Hide, I Geoff ^b   Heidenreich, Olaf ^a   Vormoor, Josef ^a,b   Maxwell, Ross J ^a   Bacon, Chris M ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d Epistem Ltd   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BIOLUMINESCENCE; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; CANCER GROWTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; EWING SARCOMA; HISTOLOGY; IN VIVO STUDY; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOCLAST; OSTEOID; OSTEOSARCOMA; OSTEOSARCOMA CELL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; SOFT TISSUE TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FEMALE; FLUORODEOXYGLUCOSE F18; HETEROGRAFTS; HUMANS; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MALE; MICE; OSTEOLYSIS; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; SARCOMA, EWING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896907722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085128     Document Type: Article

References (41)

1. Coleman RE (2001) Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176. (Pubitemid 32452017)
2. Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32: 73-84. (Pubitemid 24322250)
3. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243-6249.
4. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168: 1005-1007.
5. Ritter J, Bielack SS (2010) Osteosarcoma. Ann Oncol 21, suppl 7: 320-325.
6. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, et al. (2001) Localized Ewing tumour of bone: Final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 19: 1818-1829. (Pubitemid 32230885)
7. Paulussen M, Ahrens S, Craft AW, Dunst J, Fröhlich B, et al. (1998) Ewing's tumours with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 16: 3044-3052. (Pubitemid 28417425)
8. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, et al. (1998) Primary metastatic (stage IV) Ewing tumour: Survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 9: 275-281. (Pubitemid 28186797)
9. Nargund VH, Raghavan D, Sandler HM (2007) Urological oncology. Springer, London, UK.
10. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
11. Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198: 11-26. (Pubitemid 24159061)
12. Nagle RB, Knox JD, Wolf C, Boden GT, Cress AE (1994) Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem 19: 232-237. (Pubitemid 24306473)
13. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z (1993) Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53: 4493-4498. (Pubitemid 23304370)
14. Montague R, Hart CA, George NJ, Ramani VA, Brown MD, et al. (2004) Differential inhibition of invasion and proliferation by bisphosphonates: Antimetastatic potential of Zoledronic acid in prostate cancer. Eur Urol 46: 389-401.
15. Dalal S, Burchill SA (2009) Preclinical evaluation of vascular disrupting agents in Ewing's sarcoma family of tumours. Eur J Cancer 45: 713-722.
16. Vormoor J, Baersch G, Decker S Hotfilder M, Schäfer KL, et al. (2001) Establishment of an in vivo model for pediatric Ewing tumours by transplantation into NOD/scid mice. Pediatr Res 49: 332-341. (Pubitemid 32205231)
17. Mazurier F, Doedens M, Gan OI, Dick JE (2003) Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 9: 959-963. (Pubitemid 36889941)
18. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, et al. (2002) Establishment and characterization of osseous prostate cancer models: Intratibial injection of human prostate cancer cells. Prostate 52: 20-33. (Pubitemid 34553189)
19. Odri GA, Dumoucel S, Picarda G Battaglia S, Lamoureux F, et al. (2010) Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 70: 7610-7619.
20. Hauer K, Calzada-Wack J, Steiger K, Grunewald TG, Baumhoer D, et al. (2013) DKK2 Mediates Osteolysis, Invasiveness, and Metastatic Spread in Ewing Sarcoma. Cancer Res 73 (2): 967-977.
21. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, et al. (1984) Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 311: 584-585. (Pubitemid 15189210)
22. van Valen F, Winkelmann W, Jürgens H (1992) Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J Cancer Res Clin Oncol 118: 269-275.
23. Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumour cell lines producing tumours in nude mice. J Natl Cancer Inst 59: 221-226. (Pubitemid 8144854)
24. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, et al. (1984) Metastatic behavior of human tumour cell lines grown in the nude mouse. Cancer Res 44: 3522-3529. (Pubitemid 14098607)
25. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig Urol 17: 16-23. (Pubitemid 9239413)
26. Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, et al. (2012) Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 27: 718-721.
27. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489. (Pubitemid 40663843)
28. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, et al. (1998) Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br. J. Haematol 103: 335-342. (Pubitemid 28522436)
29. le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, et al. (2008) In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14: 47-58. (Pubitemid 351885495)
30. Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, et al. (2009) Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo 23: 903-909.
31. Zhou Z, Guan H, Duan X, Kleinerman ES (2005) Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104: 1713-1720. (Pubitemid 41437436)
32. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, et al. (2009) Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model. Clin Cancer Res 15: 3451-3461.
33. Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, et al. (2011) The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res 26: 1283-1294.
34. Henry MD, Silva MD, Wen S, Siebert E, Solin E, et al. (2005) Spiculated Periosteal Response Induced by Intraosseous Injection of 22Rv1 Prostate Cancer Cells Resembles Subset of Bone Metastases in Prostate Cancer Patients. Prostate 65: 347-354. (Pubitemid 41759967)
35. Soos G, Jones RF, Haas GP, Wang CY (1997) Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res 17: 4253-4258. (Pubitemid 28081696)
36. Winter GE, Rix U, Lissat A, Stukalov A, Mü llner MK, et al. (2011) An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol Cancer Ther 10: 1846-1856.
37. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, et al. (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma Nat Med 15: 750-756.
38. Franzius C, Hotfilder M, Poremba C, Hermann S, Schäfers K, et al. (2006) Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl Med Mol Imaging 33: 1432-1441. (Pubitemid 44885409)
39. Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, et al. (2013) Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: Effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. J Hematol Oncol 6: 10 doi: 10.1186/1756- 8722-6-10.
40. Reinus WR, Gilula LA, IESS committee (1984) Radiology of Ewing's sarcoma: Intergroup Ewing's sarcoma study (IESS). Radiographics 4: 929-944.
41. Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: A fatal attraction. Nat Rev Cancer 11: 411-425.